Ergoloid Mesylates
Loading...Ergoloid Mesylates Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia).
Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see ). CONTRAINDICATIONS
The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time.
The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.
History
There is currently no drug history available for this drug.
Other Information
Each tablet for oral use contains ergoloid mesylates USP; a mixture of the methanesulfonate salt of the following hydrogenated alkaloids:
| R | |
| Dihydroergocornine | -CH(CH ) 32 |
| Dihydroergocristine | -CH C H 265 |
| Dihydro-α-ergocryptine | -CH CH(CH ) 232 |
| Dihydro-β-ergocryptine | -CH(CH )CH CH 323 |
C H N O • CH O S (dihydroergocornine mesylate) 659.79 31415543
C H N O • CH O S (dihydroergocristine mesylate) 707.84 35415543
C H N O • CH O S (dihydro-α-ergocryptine mesylate) 673.82 32435543
C H N O • CH O S (dihydro-β-ergocryptine mesylate) 673.82 32435543
|
|
| 1 mg | |
| Dihydroergocristine mesylate | 0.333 mg |
| Dihydroergocornine mesylate | 0.333 mg |
| Dihydroergocryptine mesylate * | 0.333 mg |
Inactive ingredients for oral tablets are: butylated hydroxyanisol, hydrogenated vegetable oil, lactose, mannitol, polyvinyl pyrrollidone, corn starch, stearic acid and talc.
Sources
Ergoloid Mesylates Manufacturers
-
Carilion Materials Management
![Ergoloid Mesylates (Dihydroergocornine Mesylate, Dihydroergocristine Mesylate, Dihydro-.alpha.-ergocryptine Mesylate, And Dihydro-.beta.-ergocryptine Mesylate) Tablet [Carilion Materials Management]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Ergoloid Mesylates | Carilion Materials Management
1 mg three times a day.
Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.
-
Mutual Pharmaceutical Company, Inc.
Ergoloid Mesylates | Mutual Pharmaceutical Company, Inc.
1 mg three times a day.
Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.
-
Avkare, Inc.
Ergoloid Mesylates | Avkare, Inc.
1 mg three times a day.
Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.
![Ergoloid Mesylates (Dihydroergocornine Mesylate, Dihydroergocristine Mesylate, Dihydro-.alpha.-ergocryptine Mesylate, And Dihydro-.beta.-ergocryptine Mesylate) Tablet [Mutual Pharmaceutical Company, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf973160-d467-4192-a432-04c8c2140369&name=ergoloid-02.jpg)
![Ergoloid Mesylates (Dihydroergocornine Mesylate, Dihydroergocristine Mesylate, Dihydro-.alpha.-ergocryptine Mesylate, And Dihydro-.beta.-ergocryptine Mesylate) Tablet [Avkare, Inc.]](http://recallguide.cwdevelopsp.com/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
Login To Your Free Account